Skip to content

Atara Jaffe

Advanced Integrative Medical Science (AIMS) Institute, Seattle, WA USA.

2 papers in the library · 26 citations · publishing 2023-2025

Papers

Psilocybin in Palliative Care: An Update.

Current geriatrics reports January 1, 2023 Emily Whinkin, Moira Opalka, Conor Watters et al. 26 citations

Psilocybin, a tryptamine psychedelic found in certain mushrooms, shows promise for alleviating emotional and spiritual distress in palliative care patients. A review of recent research and field reports indicates that psilocybin has significant and sometimes sustained anxiolytic, antidepressant, anti-inflammatory, and entheogenic effects with a favorable safety profile. However, the research has limitations, including selection bias toward healthy, white, financially privileged individuals and follow-up periods too short to assess long-term psychospiritual benefits and quality of life. Major legal, ethical, and financial barriers to access exist, likely worsened for geriatric and palliative care patients. More large-scale controlled trials are needed.

Gut-Mind Interactions in Psychedelic Healing: A Case Study Assessing the Effects of Huachuma and Ayahuasca on the Mind and Microbiome.

Journal of restorative medicine January 1, 2025 Payton Follestad, Patricia Filbin, Brice Thompson et al.

A 35-year-old woman with prior psychedelic experience took Ayahuasca and Huachuma (San Pedro cactus) in separate ceremonies. Both medicines sharply reduced her depression scores (Ayahuasca: from 18 to 6; Huachuma: from 12 to 2 on the Hamilton Depression Rating Scale) and increased her feelings of connectedness (Ayahuasca: from 62.3% to 95.37%; Huachuma: from 58.32% to 84.65% on the Watts Connectedness Scale). Stool samples showed that each medicine shifted the gut microbiome differently, but both reduced pro-inflammatory bacteria, normalized inflammation-linked species, and increased beneficial butyrate-producing bacteria. These microbial changes aligned with improved mood and reduced inflammation, suggesting that psychedelics may improve mental health partly through the microbiota-gut-brain axis.